Breaking News Instant updates and real-time market news.

2019-01-07 06:25:09 FANG Diamondback Energy $99.83 / +3.67 (+3.82%) 06:25 01/07/19 01/07 06:25 01/07/19 06:25	Diamondback Energy upgraded to Outperform from Market Perform at BMO Capital
FANG Diamondback Energy $99.83 / +3.67 (+3.82%) 12/20/18 Wells Fargo Diamondback Energy price target lowered to $151 from $157 at Wells Fargo 12/20/18 KeyBanc Diamondback Energy initiated with an Overweight at KeyBanc 12/20/18 Imperial Capital Diamondback Energy price target lowered to $140 from $170 at Imperial Capital 12/11/18 Citi Diamondback Energy resumed with a Buy at Citi

TODAY'S FREE FLY STORIES

Downgrade	Weir Group downgraded to Hold from Buy at Deutsche Bank » 05:27 03/04/21 03/04 05:27 03/04/21 05:27 WEGRY Weir Group $0.00 / + (+0.00%) Deutsche Bank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research WEGRY Weir Group $0.00 / + (+0.00%) 03/03/21 RBC Capital Weir Group price target raised to 2,470 GBp from 2,190 GBp at RBC Capital 02/11/21 Goldman Sachs Weir Group reinstated with a Neutral at Goldman Sachs 02/08/21 Morgan Stanley Weir Group upgraded to Overweight from Equal Weight at Morgan Stanley 01/13/21 Barclays Weir Group price target raised to 2,350 GBp from 2,000 GBp at Barclays
Hot Stocks	SailPoint announces expansion into Japan » 05:26 03/04/21 03/04 05:26 03/04/21 05:26 SAIL SailPoint $55.12 / -4.02 (-6.80%) SailPoint announced its… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events SAIL SailPoint $55.12 / -4.02 (-6.80%) 03/01/21 SailPoint CEO: We have a very strong position in the market 02/18/21 SailPoint to acquire Intello, terms not stated 10/05/20 SailPoint to replace Sally Beauty in S&P 400 at open on 10/5 10/01/20 SailPoint rises 13.2% SAIL SailPoint $55.12 / -4.02 (-6.80%) 03/01/21 Needham SailPoint upgraded to Buy from Hold at Needham 03/01/21 Morgan Stanley SailPoint price target raised to $75 from $71 at Morgan Stanley 02/16/21 Canaccord SailPoint price target raised to $70 from $53 at Canaccord 01/27/21 RBC Capital SailPoint price target raised to $68 from $55 at RBC Capital SAIL SailPoint $55.12 / -4.02 (-6.80%) 02/25/21 SailPoint sees FY21 adjusted EPS (10c)-(1c), consensus 17c 02/25/21 SailPoint sees Q1 adjusted EPS approximately (1c), consensus 0c 02/25/21 SailPoint reports Q4 adjusted EPS 10c, consensus 0c 11/05/20 SailPoint sees FY20 adjusted EPS 27c-29c, consensus 11c SAIL SailPoint $55.12 / -4.02 (-6.80%) 12/21/20 Analysts move to sidelines on SolarWinds following cyberattack 10/01/20 Fly Intel: Pre-market Movers 09/30/20 Fly Intel: After-Hours Movers 04/15/21 Cybersecurity
Recommendations	Airbus price target raised to EUR 120 from EUR 107 at JPMorgan » 05:25 03/04/21 03/04 05:25 03/04/21 05:25 EADSY Airbus $0.00 / + (+0.00%) JPMorgan analyst David… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly EADSY Airbus $0.00 / + (+0.00%) 02/26/21 JetBlue takes delivery of first Airbus A321neo featuring reimagined Mint 02/23/21 Spirit AeroSystems announces backlog of approximately $34B at end of Q4 02/18/21 Airbus sees at least EBIT adjusted of EUR2B in 2021 02/17/21 American Airlines sees Q1 system capacity down 45%, may retire more aircraft EADSY Airbus $0.00 / + (+0.00%) 03/01/21 Morgan Stanley Airbus price target lowered to EUR 111 from EUR 112 at Morgan Stanley 03/01/21 Morgan Stanley Boeing price target raised to $250 from $230 at Morgan Stanley 02/22/21 JPMorgan Airbus price target lowered to EUR 107 from EUR 109 at JPMorgan 02/22/21 Societe Generale Airbus price target raised to EUR 76 from EUR 60 at Societe Generale EADSY Airbus $0.00 / + (+0.00%) 02/18/21 Airbus reports FY20 revenue EUR49.9B vs. EUR 70.5B last year 10/29/20 Airbus reports 9-month EPS EUR (3.43) vs. EUR 2.81 last year EADSY Airbus $0.00 / + (+0.00%) 02/26/21 Airbus developing hybrid-electric propulsion technology, Reuters reports 02/21/21 Airbus chief urges transatlantic trade war ceasefire, Reuters reports 02/15/21 Lufthansa trying to swap orders to smaller jets, Bloomberg reports 02/11/21 Southwest in talks for at least 300 new 150-seat planes, Air Current says EADSY Airbus $0.00 / + (+0.00%) 01/02/21 Week in review: How Trump's policies moved stocks 12/31/20 Fly Intel: Wall Street's top stories for Thursday 12/31/20 Fly Intel: Wall Street's top stories at midday 11/18/20 Boeing rises after FAA lifts order grounding 737 MAX
Upgrade	Safran upgraded to Overweight from Neutral at JPMorgan » 05:25 03/04/21 03/04 05:25 03/04/21 05:25 SAFRY Safran $0.00 / + (+0.00%) JPMorgan analyst David… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research Periodicals SAFRY Safran $0.00 / + (+0.00%) 03/03/21 Barclays Safran downgraded to Equal Weight from Overweight at Barclays 03/02/21 Morgan Stanley Safran price target lowered to EUR 85 from EUR 87 at Morgan Stanley 02/26/21 Credit Suisse Safran price target lowered to EUR 97 from EUR 102 at Credit Suisse 02/11/21 Morgan Stanley Safran price target raised to EUR 87 from EUR 85 at Morgan Stanley SAFRY Safran $0.00 / + (+0.00%) 02/11/21 Southwest in talks for at least 300 new 150-seat planes, Air Current says 10/30/20 Safran CEO says new Boeing aircraft unlikely in near future, Reuters says
Hot Stocks	GC Pharma to support Moderna distribution of 40M doses of COVID-19 Vaccine » 05:23 03/04/21 03/04 05:23 03/04/21 05:23 MRNA Moderna $131.20 / -15.53 (-10.58%) GC Pharma announced that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options MRNA Moderna $131.20 / -15.53 (-10.58%) 02/25/21 Moderna's chief medical officer Tal Zaks to leave company in late September 02/24/21 Moderna makes new capital investment to boost manufacturing capacity 02/24/21 Moderna ships mRNA-1273.351 to NIH for clinical study 02/24/21 Takeda provides update on Novavax, Moderna COVID-19 vaccine candidates in Japan MRNA Moderna $131.20 / -15.53 (-10.58%) 03/01/21 Chardan Moderna price target raised to $182 from $107 at Chardan 02/26/21 Barclays Moderna price target raised to $178 from $169 at Barclays 02/26/21 Brookline Moderna price target raised to $205 from $180 at Brookline 02/25/21 Piper Sandler Moderna transitioning into profitable company, says Piper Sandler MRNA Moderna $131.20 / -15.53 (-10.58%) 02/25/21 Moderna reports Q4 EPS (69c), consensus (35c) 02/24/21 Notable companies reporting before tomorrow's open 02/24/21 Notable companies reporting before tomorrow's open 10/29/20 Moderna reports Q3 EPS (59c), consensus (43c) 19 May MRNA Moderna $131.20 / -15.53 (-10.58%) 03/03/21 Some Catholic bishops advise against certain Covid-19 vaccines, WSJ reports 02/28/21 AstraZeneca sells stake in Moderna for over $1B, The Times reports 02/17/21 Moderna to supply EU with another 150M vaccine doses in 2021, FT reports 02/12/21 FDA tells Moderna it can boost vaccine supply in each vial, NY Times reports MRNA Moderna $131.20 / -15.53 (-10.58%) 02/25/21 Fly Intel: Pre-market Movers 02/24/21 Fly Intel: After-Hours Movers 02/12/21 Fly Intel: Wall Street's top stories for Friday 02/12/21 Fly Intel: Wall Street's top stories at midday 03/16/21 31st Annual Healthcare Virtual Conference MRNA Moderna $131.20 / -15.53 (-10.58%) 03/01/21 Moderna call volume above normal and directionally bullish 02/01/21 Moderna call volume above normal and directionally bullish 01/25/21 Moderna call volume above normal and directionally bullish 12/17/20 Moderna call volume above normal and directionally bullish

Downgrade	Dycom downgraded to Equal Weight from Overweight at Wells Fargo » 05:21 03/04/21 03/04 05:21 03/04/21 05:21 DY Dycom $87.11 / +9.59 (+12.37%) Wells Fargo analyst Eric… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events DY Dycom $87.11 / +9.59 (+12.37%) 03/03/21 Dycom announces new $150M share repurchase plan 01/15/21 Dycom COO sells 52K shares of common stock 12/16/20 Dycom COO sells 150.1K shares of common stock 11/24/20 Dycom falls -17.3% DY Dycom $87.11 / +9.59 (+12.37%) 01/27/21 KeyBanc Dycom upgraded to Overweight at KeyBanc 01/27/21 KeyBanc Dycom upgraded to Overweight from Sector Weight at KeyBanc 01/07/21 B. Riley Securities Dycom price target raised to $97 from $92 at B. Riley Securities 11/25/20 DA Davidson Dycom price target raised to $80 from $60 at DA Davidson DY Dycom $87.11 / +9.59 (+12.37%) 03/03/21 Dycom sees Q1 revenue in-line to modestly lower than Q4, consensus $786.14M 03/03/21 Dycom reports Q4 EPS (7c), consensus 4c 11/24/20 Dycom sees modestly lower contract revenues in Q4, consensus $744.13M 11/24/20 Dycom reports Q3 adj. EPS $1.06, consensus $1.05 DY Dycom $87.11 / +9.59 (+12.37%) 03/03/21 Fly Intel: Pre-market Movers 03/31/21 Dycom
Hot Stocks	Regeneron, Sanofi announce FDA acceptance of Dupixent sBLA » 05:21 03/04/21 03/04 05:21 03/04/21 05:21 REGN Regeneron $446.60 / -8.71 (-1.91%) , SNY Sanofi $45.46 / -0.495 (-1.08%) Regeneron (REGN) and… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options REGN SNY REGN Regeneron $446.60 / -8.71 (-1.91%) 03/03/21 Kiniksa jumps 10% to $24 per share after disclosing supply deal with Regeneron 02/28/21 Regeneron announces Phase 2 data evaluating antibody cocktail REGN1908-1909 02/26/21 Regeneron announces CHMP recommendation for COVID-19 antibody cocktail 02/24/21 Decibel Therapeutics presents preclinical findings on DB-OTO SNY Sanofi $45.46 / -0.495 (-1.08%) 02/22/21 Regeneron announces third FDA approval for PD-1 inhibitor Libtayo 02/22/21 Sanofi, GSK initiate Phase 2 study of COVID-19 vaccine candidate 02/12/21 Sanofi offers to acquire Kiadis Pharma shares for EUR 5.45 per share in cash 02/12/21 Regeneron, Sanofi announce results from Libtayo comparative study published REGN SNY REGN Regeneron $446.60 / -8.71 (-1.91%) 02/23/21 Credit Suisse Regeneron price target raised to $760 from $753 at Credit Suisse 02/16/21 Cantor Fitzgerald Regeneron price target lowered to $656 from $696 at Cantor Fitzgerald 02/08/21 SVB Leerink Regeneron price target raised to $640 from $623 at SVB Leerink 02/08/21 Credit Suisse Regeneron price target lowered to $753 from $758 at Credit Suisse SNY Sanofi $45.46 / -0.495 (-1.08%) 02/23/21 BofA BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list 02/10/21 Morgan Stanley Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley 02/05/21 Piper Sandler Piper reiterates Overweight on Kymera after Sanofi capital markets day 01/19/21 UBS Sanofi price target lowered to EUR 99 from EUR 100 at UBS REGN SNY REGN Regeneron $446.60 / -8.71 (-1.91%) 02/05/21 Regeneron reports Q4 EPS $9.53, consensus $8.39 02/04/21 Notable companies reporting before tomorrow's open 02/04/21 Notable companies reporting before tomorrow's open 11/05/20 Regeneron reports Q3 EPS $8.36, consensus $7.13 SNY Sanofi $45.46 / -0.495 (-1.08%) 02/05/21 Sanofi reports Q4 business EPS EUR 1.22, flat vs. last year 10/29/20 Sanofi reports Q3 business EPS EUR 1.83, up 0.5% from last year 27 May REGN SNY REGN Regeneron $446.60 / -8.71 (-1.91%) 02/11/21 Amgen loses appeal to revive PCSK9 antibody patent suit, Bloomberg reports 12/30/20 Fresenius to administer Lilly, Regeneron COVID antibody drugs, Reuters says 12/04/20 Regeneron must face DOJ suit citing kickbacks, Bloomberg says 11/17/20 Regeneron says Roche completed early tests to make COVID drug, Reuters says SNY Sanofi $45.46 / -0.495 (-1.08%) 02/15/21 CEO says Sanofi mRNA vaccine won't be ready this year, Bloomberg reports 02/15/21 Bristol-Myers, Sanofi to pay $834M over Plavix, Bloomberg reports 02/11/21 Amgen loses appeal to revive PCSK9 antibody patent suit, Bloomberg reports 12/31/20 Drugmakers to hike U.S. prices on over 200 drugs, Reuters reports REGN SNY REGN Regeneron $446.60 / -8.71 (-1.91%) 02/05/21 Fly Intel: Pre-market Movers 01/26/21 Fly Intel: Wall Street's top stories for Tuesday 01/26/21 Fly Intel: Wall Street's top stories at midday 01/12/21 Fly Intel: After-Hours Movers SNY Sanofi $45.46 / -0.495 (-1.08%) 02/22/21 Fly Intel: Wall Street's top stories for Monday 02/22/21 Fly Intel: Wall Street's top stories at midday 12/31/20 Fly Intel: Wall Street's top stories for Thursday 12/26/20 Week in review: How Trump's policies moved stocks 03/16/21 31st Annual Healthcare Virtual Conference 05/18/21 PDUFA Date for Avalglucosidase Alfa REGN REGN Regeneron $446.60 / -8.71 (-1.91%) 01/13/21 Early notable gainers among liquid option names on January 13th 12/18/20 Early notable gainers among liquid option names on December 18th 11/06/20 Regeneron put volume heavy and directionally bearish 10/08/20 Unusually active option classes on open October 8th
Downgrade	Retail Properties downgraded to Sector Weight from Overweight at KeyBanc » 05:20 03/04/21 03/04 05:20 03/04/21 05:20 RPAI Retail Properties of America $10.99 / +0.51 (+4.87%) KeyBanc analyst Todd… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events RPAI Retail Properties of America $10.99 / +0.51 (+4.87%) 12/08/20 Retail Properties of America raises quarterly dividend to 6c from 5c per share 09/08/20 Retail Properties of America resumes dividend payment and provides update RPAI Retail Properties of America $10.99 / +0.51 (+4.87%) 12/15/20 Citi Retail Properties of America price target raised to $9.50 from $7 at Citi 11/10/20 Compass Point Compass Point upgrades four retail REITs to Neutral after Pfizer 'game changer' 11/09/20 Compass Point Retail Properties of America upgraded to Neutral from Sell at Compass Point 07/27/20 Deutsche Bank Deutsche Bank downgrades Retail Properties of America on retail REIT headwinds RPAI Retail Properties of America $10.99 / +0.51 (+4.87%) 02/16/21 Retail Properties of America sees FY21 operating FFO 76c-84c 02/16/21 Retail Properties of America reports Q4 operating FFO 20c, consensus 21c 11/02/20 Retail Properties of America reports Q3 operating FFO 21, consensus 20c 05/05/21 Retail Properties of America - RPAI
Upgrade	Kite Realty Group upgraded to Overweight from Sector Weight at KeyBanc » 05:20 03/04/21 03/04 05:20 03/04/21 05:20 KRG Kite Realty Group $19.46 / +0.31 (+1.62%) KeyBanc analyst Todd… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events KRG Kite Realty Group $19.46 / +0.31 (+1.62%) 02/23/21 Kite Realty Group board authorizes new $150M share buyback 09/14/20 Kite Realty Group collects over 89% of Q3 base rent, recoveries KRG Kite Realty Group $19.46 / +0.31 (+1.62%) 12/10/20 Wells Fargo Kite Realty Group upgraded to Overweight at Wells Fargo 12/10/20 Wells Fargo Kite Realty Group upgraded to Overweight from Equal Weight at Wells Fargo 08/19/20 Fly Intel: Top five analyst downgrades 08/19/20 Compass Point Compass Point downgrades Regency Centers on 'tactical valuation call' KRG Kite Realty Group $19.46 / +0.31 (+1.62%) 02/11/21 Kite Realty Group sees FY21 adjusted FFO $1.24-$1.34, consensus $1.32 02/11/21 Kite Realty Group reports Q4 adjusted FFO 33c, consensus 31c 03/16/21 Kite Realty Group 03/16/21 Kite Realty Group 05/12/21 Kite Realty Group Trust
Upgrade	Site Centers upgraded to Overweight from Sector Weight at KeyBanc » 05:19 03/04/21 03/04 05:19 03/04/21 05:19 SITC Site Centers $12.89 / +0.1 (+0.78%) KeyBanc analyst Todd… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events SITC Site Centers $12.89 / +0.1 (+0.78%) 01/12/21 Site Centers provides Q4 operational update SITC Site Centers $12.89 / +0.1 (+0.78%) 02/23/21 Mizuho Site Centers price target raised to $13 from $10.50 at Mizuho 01/14/21 Piper Sandler Site Centers upgraded to Overweight from Neutral at Piper Sandler 12/15/20 Citi Site Centers price target raised to $11 from $8.50 at Citi 12/11/20 Truist Site Centers price target raised to $10 from $7 at Truist SITC Site Centers $12.89 / +0.1 (+0.78%) 02/18/21 Site Centers sees 2021 operating FFO 90c-$1.00, consensus 98c 02/18/21 Site Centers reports Q4 operating FFO 25c, consensus 24c 10/27/20 Site Centers reports Q3 operating FFO 23c, consensus 23c 02 Mar 03/17/21 Site Centers

Downgrade	Kering downgraded to Add from Buy at AlphaValue » 05:19 03/04/21 03/04 05:19 03/04/21 05:19 PPRUY Kering $0.00 / + (+0.00%) AlphaValue downgraded… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research PPRUY Kering $0.00 / + (+0.00%) 03/01/21 Jefferies Kering upgraded to Buy from Hold at Jefferies 02/22/21 Credit Suisse Kering price target lowered to EUR 635 from EUR 675 at Credit Suisse 02/18/21 UBS Kering price target lowered to EUR 568 from EUR 624 at UBS 02/16/21 Morgan Stanley Kering price target raised to EUR 590 from EUR 550 at Morgan Stanley
Upgrade	EDP Renovaveis upgraded to Buy from Hold at Societe Generale » 05:17 03/04/21 03/04 05:17 03/04/21 05:17 EDRVF EDP Renovaveis $0.00 / + (+0.00%) Societe Generale analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research EDRVF EDP Renovaveis $0.00 / + (+0.00%) 02/26/21 Barclays EDP Renovaveis price target lowered to EUR 20.30 from EUR 24.80 at Barclays 02/26/21 Exane BNP Paribas EDP Renovaveis upgraded to Outperform from Neutral at Exane BNP Paribas 02/26/21 Exane BNP Paribas EDP Renovaveis upgraded to Outperform from Neutral at Exane BNP Paribas 02/22/21 JPMorgan EDP Renovaveis price target raised to EUR 22.60 from EUR 21.30 at JPMorgan
Downgrade	Idemitsu Kosan downgraded to Neutral from Outperform at SMBC Nikko » 05:15 03/04/21 03/04 05:15 03/04/21 05:15 IDKOY Idemitsu Kosan $0.00 / + (+0.00%) SMBC Nikko analyst Koji… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research IDKOY Idemitsu Kosan $0.00 / + (+0.00%) 01/26/21 Jefferies Idemitsu Kosan downgraded to Hold from Buy at Jefferies 06/09/20 Daiwa Idemitsu Kosan downgraded to Neutral from Buy at Daiwa
Upgrade	Inpex upgraded to Outperform from Neutral at SMBC Nikko » 05:15 03/04/21 03/04 05:15 03/04/21 05:15 IPHXY Inpex $0.00 / + (+0.00%) SMBC Nikko analyst Koji… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Downgrade	Mitsubishi Estate Co. downgraded to Neutral from Buy at Mizuho » 05:14 03/04/21 03/04 05:14 03/04/21 05:14 MITEY Mitsubishi Estate Co. $0.00 / + (+0.00%) Mizuho analyst Yoshihiro… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research MITEY Mitsubishi Estate Co. $0.00 / + (+0.00%) 10/07/20 Goldman Sachs Mitsubishi Estate Co. upgraded to Buy from Neutral at Goldman Sachs 05/06/20 Goldman Sachs Mitsubishi Estate Co. downgraded to Neutral from Buy at Goldman Sachs 04/06/20 Jefferies Mitsubishi Estate Co. initiated with a Buy at Jefferies

Hot Stocks	Galapagos announces interim results from MANTA, MANTA-RAy studies » 05:13 03/04/21 03/04 05:13 03/04/21 05:13 GLPG Galapagos $82.20 / -2.63 (-3.10%) , GILD Gilead $62.76 / -0.245 (-0.39%) Galapagos (GLPG)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options GLPG GILD GLPG Galapagos $82.20 / -2.63 (-3.10%) 02/10/21 Galapagos, Gilead discontinue Phase 3 ISABELA trials 02/10/21 Gilead, Galapagos discontinue ISABELA Phase 3 trials in IPF 01/21/21 Galapagos announces NICE recommendation for Jyseleca on NHS 12/15/20 Galapagos to assume development, manufacturing, other rights for Jyseleca GILD Gilead $62.76 / -0.245 (-0.39%) 02/17/21 Study funded by NIH to evaluate Gilead's remdesivir for COVID-19 in pregnancy 02/10/21 Gilead announces findings from a new analysis of the ZUMA-1 trial of Yescarta 02/10/21 Galapagos, Gilead discontinue Phase 3 ISABELA trials 02/10/21 Gilead, Galapagos discontinue ISABELA Phase 3 trials in IPF GLPG GILD GLPG Galapagos $82.20 / -2.63 (-3.10%) 03/02/21 Barclays Galapagos price target lowered to EUR 69 from EUR 85.50 at Barclays 02/23/21 BofA Galapagos upgraded to Neutral from Underperform at BofA 02/23/21 BofA Galapagos upgraded to Neutral from Underperform at BofA 02/19/21 Raymond James Raymond James upgrades 'heavily discounted' Galapagos to Outperform GILD Gilead $62.76 / -0.245 (-0.39%) 02/12/21 Morgan Stanley Amgen court decision may have readthrough for Gilead, says Morgan Stanley 02/11/21 Maxim Galapagos downgraded to Hold at Maxim after discontinued Phase 3 ISABELA trials 02/10/21 Maxim Maxim downgrades Galapagos after idiopathic pulmonary fibrosis failure 01/29/21 Jefferies Carvana, Walmart among 13 additions to Jefferies Franchise Picks list GLPG GILD GLPG Galapagos $82.20 / -2.63 (-3.10%) 02/18/21 Galapagos reports FY 20 EUR 530M versus EUR 886M in 2019 GILD Gilead $62.76 / -0.245 (-0.39%) 02/04/21 Gilead sees FY21 adjusted EPS $6.75-$7.45, consensus $6.85 02/04/21 Gilead reports Q4 adjusted EPS $2.19, consensus $2.15 02/04/21 Notable companies reporting after market close 01/11/21 Gilead raises FY20 adjusted EPS view to $6.98 - $7.08 from $6.25 - $6.60 GILD GILD Gilead $62.76 / -0.245 (-0.39%) 11/19/20 WHO urges doctors not to use Gilead's remdesivir for coronavirus, Bloomberg says 10/15/20 WHO study says Gilead's remdesivir has little impact on COVID mortality, FT says 10/09/20 Takeda, others testing convalescent plasma treatment in Covid, WSJ reports 09/12/20 Gilead near deal to buy Immunomedics for over $20B, WSJ reports GLPG GILD GLPG Galapagos $82.20 / -2.63 (-3.10%) 12/16/20 Fly Intel: Wall Street's top stories for Wednesday 12/16/20 Fly Intel: Wall Street's top stories at midday 12/15/20 Fly Intel: After-Hours Movers GILD Gilead $62.76 / -0.245 (-0.39%) 02/04/21 Fly Intel: After-Hours Movers 01/11/21 Fly Intel: Pre-market Movers 12/16/20 Fly Intel: Wall Street's top stories for Wednesday 12/16/20 Fly Intel: Wall Street's top stories at midday 03/02/21 41st Annual Healthcare Virtual Conference 05/07/21 Galapagos - GLPG GILD GILD Gilead $62.76 / -0.245 (-0.39%) 01/19/21 Early notable gainers among liquid option names on January 19th 01/11/21 Gilead call volume above normal and directionally bullish 12/31/20 Unusually active option classes on open December 31st 12/01/20 Gilead call volume above normal and directionally bullish
Upgrade	Kuehne & Nagel upgraded to Add from Sell at AlphaValue » 05:12 03/04/21 03/04 05:12 03/04/21 05:12 KHNGY Kuehne & Nagel $0.00 / + (+0.00%) AlphaValue analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research KHNGY Kuehne & Nagel $0.00 / + (+0.00%) 02/23/21 Bernstein Kuehne & Nagel upgraded to Outperform from Market Perform at Bernstein 01/12/21 UBS Kuehne & Nagel price target raised to CHF 201 from CHF 173 at UBS 10/22/20 Berenberg Kuehne & Nagel price target raised to CHF 165 from CHF 150 at Berenberg 10/22/20 Bernstein Kuehne & Nagel downgraded to Market Perform from Outperform at Bernstein
Upgrade	RWE AG upgraded to Buy from Hold at Societe Generale » 05:11 03/04/21 03/04 05:11 03/04/21 05:11 RWEOY RWE AG $0.00 / + (+0.00%) Societe Generale analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research RWEOY RWE AG $0.00 / + (+0.00%) 02/19/21 Barclays RWE AG price target lowered to EUR 41 from EUR 42 at Barclays 01/12/21 Barclays RWE AG price target raised to EUR 42 from EUR 40 at Barclays 01/07/21 JPMorgan RWE AG price target lowered to EUR 37.50 from EUR 38 at JPMorgan 12/08/20 Kepler Cheuvreux RWE AG upgraded to Hold from Reduce at Kepler Cheuvreux
Upgrade	Societe Generale double upgrades Reckitt Benckiser to Buy from Sell » 05:10 03/04/21 03/04 05:10 03/04/21 05:10 RBGLY Reckitt Benckiser $0.00 / + (+0.00%) Societe Generale analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research RBGLY Reckitt Benckiser $0.00 / + (+0.00%) 11/27/20 Indivior falls after Reckitt files GBP 1.07B suit over demerger RBGLY Reckitt Benckiser $0.00 / + (+0.00%) 05:07 Today Societe Generale Reckitt Benckiser upgraded to Buy from Sell at Societe Generale 02/25/21 Barclays Reckitt Benckiser price target lowered to 9,100 GBp from 9,600 GBp at Barclays 02/25/21 RBC Capital Reckitt Benckiser price target raised to 6,800 GBp at RBC Capital 02/25/21 Berenberg Reckitt Benckiser price target lowered to 8,385 GBp from 9,100 GBp at Berenberg
Upgrade	Rentokil upgraded to Add from Hold at Peel Hunt » 05:07 03/04/21 03/04 05:07 03/04/21 05:07 RTOKY Rentokil $0.00 / + (+0.00%) Peel Hunt analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research RTOKY Rentokil $0.00 / + (+0.00%) 02/02/21 Berenberg Rentokil initiated with a Sell at Berenberg 01/14/21 JPMorgan Rentokil price target raised to 595 GBp from 585 GBp at JPMorgan 01/12/21 Morgan Stanley Rentokil price target raised to 630 GBp from 620 GBp at Morgan Stanley 01/11/21 RBC Capital Rentokil price target raised to 625 GBp from 600 GBp at RBC Capital

Upgrade	Reckitt Benckiser upgraded to Buy from Sell at Societe Generale » 05:07 03/04/21 03/04 05:07 03/04/21 05:07 RBGLY Reckitt Benckiser $0.00 / + (+0.00%) Societe Generale analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research RBGLY Reckitt Benckiser $0.00 / + (+0.00%) 11/27/20 Indivior falls after Reckitt files GBP 1.07B suit over demerger RBGLY Reckitt Benckiser $0.00 / + (+0.00%) 02/25/21 Barclays Reckitt Benckiser price target lowered to 9,100 GBp from 9,600 GBp at Barclays 02/25/21 RBC Capital Reckitt Benckiser price target raised to 6,800 GBp at RBC Capital 02/25/21 Berenberg Reckitt Benckiser price target lowered to 8,385 GBp from 9,100 GBp at Berenberg 02/25/21 Jefferies Reckitt Benckiser upgraded to Hold from Underperform at Jefferies
Earnings	Baozun reports Q4 EPS 57c, consensus 56c » 05:06 03/04/21 03/04 05:06 03/04/21 05:06 BZUN Baozun $45.90 / -1.51 (-3.18%) Reports Q4 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events BZUN Baozun $45.90 / -1.51 (-3.18%) 01/26/21 Baozun, iClick Interactive announce equity investment and business cooperation 11/23/20 Baozun CFO Robin Lu to take on new role, Arthur Yu to succeed 11/11/20 Baozun reports RMB 16.5B in total order value for 11.11 festival, up 55% BZUN Baozun $45.90 / -1.51 (-3.18%) 01/26/21 Alliance Global Partners iClick Interactive Asia price target raised to $21 from $18 at Alliance Global 01/26/21 Benchmark iClick, Baozun partnership a strategic positive for both, says Benchmark 01/26/21 CICC Baozun downgraded to Market Perform from Outperform at CICC 01/25/21 CLSA Baozun upgraded to Buy from Outperform at CLSA BZUN Baozun $45.90 / -1.51 (-3.18%) 11/23/20 Baozun reports Q3 EPS 22c, consensus 20c BZUN Baozun $45.90 / -1.51 (-3.18%) 11/23/20 Fly Intel: Pre-market Movers 07:00 Today Baozun - BZUN
Upgrade	Whitbread upgraded to Overweight from Neutral at JPMorgan » 05:06 03/04/21 03/04 05:06 03/04/21 05:06 WTBDY Whitbread $0.00 / + (+0.00%) JPMorgan analyst Estelle… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research WTBDY Whitbread $0.00 / + (+0.00%) 02/18/21 Morgan Stanley Whitbread price target raised to 3,500 GBp from 3,000 GBp at Morgan Stanley 02/12/21 Berenberg Whitbread price target raised to 3,600 GBp from 2,500 GBp at Berenberg 01/13/21 Peel Hunt Whitbread downgraded to Hold from Buy at Peel Hunt 12/17/20 Societe Generale Whitbread price target raised to 2,780 GBp from 2,030 GBp at Societe Generale
Downgrade	InterContinental downgraded to Underweight from Neutral at JPMorgan » 05:05 03/04/21 03/04 05:05 03/04/21 05:05 IHG InterContinental $71.29 / +0.19 (+0.27%) JPMorgan analyst Estelle… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research IHG InterContinental $71.29 / +0.19 (+0.27%) 09/18/20 InterContinental falls -4.2% 09/18/20 InterContinental falls -4.3% IHG InterContinental $71.29 / +0.19 (+0.27%) 03/03/21 JPMorgan InterContinental downgraded to Underweight from Neutral at JPMorgan 02/24/21 Deutsche Bank InterContinental price target lowered to 5,380 GBp at Deutsche Bank 02/24/21 Deutsche Bank InterContinental downgraded to Hold from Buy at Deutsche Bank 02/22/21 Peel Hunt InterContinental downgraded to Reduce from Hold at Peel Hunt
Upgrade	Passage Bio upgraded to Buy from Neutral at Goldman Sachs » 04:58 03/04/21 03/04 04:58 03/04/21 04:58 PASG Passage Bio $20.12 / +0.48 (+2.44%) Goldman Sachs analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options PASG Passage Bio $20.12 / +0.48 (+2.44%) 03/03/21 Passage Bio announces anticipated upcoming milestones 02/19/21 Passage Bio appoints Maxine Gowen to board of directors 02/08/21 Passage Bio's IND application for Krabbe disease candidate cleared by FDA 01/28/21 Passage Bio annoounces FDA IND clearance for PBFT02 PASG Passage Bio $20.12 / +0.48 (+2.44%) 02/04/21 Fly Intel: Top five analyst initiations 02/04/21 Guggenheim Passage Bio initiated with a Buy at Guggenheim 01/25/21 Citi Citi upgrades Passage Bio to Buy after pullback and ahead of data 01/25/21 Citi Passage Bio upgraded to Buy from Neutral at Citi PASG Passage Bio $20.12 / +0.48 (+2.44%) 03/03/21 Passage Bio reports Q4 EPS (85c), consensus (70c) 11/10/20 Passage Bio reports Q3 EPS (63c), consensus (76c) 22 Jan PASG Passage Bio $20.12 / +0.48 (+2.44%) 01/22/21 Fly Intel: Wall Street's top stories for Friday 01/22/21 Fly Intel: Wall Street's top stories at midday PASG Passage Bio $20.12 / +0.48 (+2.44%) 12/09/20 Nine new option listings on December 9th

Events

Earnings calls, analyst events, roadshows and more

BZUN
Today at 07:00

Baozun - BZUN Conference Calls
QTT
Today at 07:00

Qutoutiao - QTT Conference Calls
Today at 07:30

Challenger Job-Cut Report Level: February 2021 Government Event
ATC
Today at 08:00

Atotech - ATC Conference Calls
WVE
Today at 08:00

Wave Life Sciences - WVE Conference Calls
FULC
Today at 08:00

Fulcrum Therapeutics - FULC Conference Calls
HCM
Today at 08:00

Hutchison China MediTech - HCM Conference Calls
BALY
Today at 08:00

Bally's - BALY Conference Calls
Today at 08:00

Consumer Data Analytics Industry Meetings
Today at 08:30

Productivity & Costs: Non-farm Poductivity Annual Rate: Q4(r):2020 Government Event

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	SWTX X SWTX SpringsWorks Therapeutics Block Trade Managers: Morgan Stanley Priced at: $84.00 1.2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRT X VRT Vertiv Holdings Block Trade Managers: JPMorgan Priced at: $20.70 17.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan Priced at: $120.00 2.08M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SYNH X SYNH Syneos Health Secondary Managers: Goldman Sachs Priced at: $74.95 7M Shares EAF X EAF GrafTech Spot Secondary Managers: Morgan Stanley Priced at: $11.88 30M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FRC X FRC First Republic Spot Secondary Managers: BofA, JPMorgan & Morgan Stanley Priced at: $166.50 1.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HLNE X HLNE Hamilton Lane Spot Secondary Managers: JPMorgan Priced at: $88.25 1.45M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial JELD X JELD Jeld-Wen Spot Secondary Managers: Goldman Sachs Priced at: $29.25 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RCL X RCL Royal Caribbean Spot Secondary Managers: Morgan Stanley Priced at: $91.00 16.938M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SITC X SITC Site Centers Spot Secondary Managers: Morgan Stanley & Wells Fargo Priced at: $13.20 15M Shares WSC X WSC WillScot Mobile Mini Spot Secondary Managers: Morgan Stanley Priced at: $27.20 12.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	OSCR X OSCR Oscar Health IPO Managers: Goldman Sachs, Morgan Stanley & Allen & Co., Wells Fargo, Credit Suisse, BofA, Cowen, LION, Ramirez, SIEB Priced at: $39.00 31M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ASLN X ASLN Aslan Pharmaceuticals Secondary Managers: Jefferies & Piper Sandler Priced at: $4.00 15M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CDLX X CDLX Cardlytics Secondary Managers: BofA, JPMorgan, Wells Fargo & Raymond James Priced at: $130.00 3.85M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial HSKA X HSKA Heska Secondary Managers: JPMorgan & Piper Sandler Priced at: $186.00 941K Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INDT X INDT Indus Realty Trust Secondary Managers: Morgan Stanley, Citi & Baird, BTIG, JMP Securities, JPMorgan Priced at: $60.00 1.75M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MORF X MORF Morphic Secondary Managers: Jefferies, Cowen, BMO Capital & RBC Capital Priced at: $70.00 3.5M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ICAD X ICAD iCAD Spot Secondary Managers: Guggenheim Priced at: $18.00 1.222M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MGY X MGY Magnolia Oil & Gas Spot Secondary Managers: Credit Suisse & Citi Priced at: $10.50 17M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ORC X ORC Orchid Island Capital Spot Secondary Managers: JPMorgan Priced at: $5.55 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PLXP X PLXP PLx Pharma Spot Secondary Managers: Raymond James & Oppenheimer Priced at: $8.00 7.88M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RDHL X RDHL RedHill Biopharma Spot Secondary Managers: H.C. Wainwright Priced at: $8.00 4.375M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SSYS X SSYS Stratasys Spot Secondary Managers: JPMorgan & Stifel Priced at: $29.00 6.897M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	INNV X INNV InnovAge IPO Managers: JPMorgan, Barclays, Goldman Sachs & Citi, Baird, William Blair, Piper Sandler, Capital One, Loop Capital, SIEB, Roberts & Ryans Priced at: $21.00 16.667M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SLQT X SLQT SelectQuote Secondary Managers: Credit Suisse, Morgan Stanley, Goldman Sachs, RBC Capital, Barclays, Citi, Evercore ISI & Jefferies, Cantor Fitzgerald, Keefe Bruyette, Piper Sandler, Drexel Hamilton Priced at: $27.50 10.6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VICI X VICI VICI Properties Secondary Managers: Morgan Stanley, BofA, Citi & Deutsche Bank Priced at: $29.00 60M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	GROY X GROY Gold Royalty IPO Managers: H.C. Wainwright & BMO Capital, CIBC, HAYW, Raymond James, Roth Capital, Scotiabank, Sprott, TD Securities $5.00 16M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	AMRK X AMRK A-Mark Precious Metals Secondary Managers: DA Davidson & Roth Capital, CIBC $27.97 2.5M Shares COHU X COHU Cohu Secondary Managers: Citi, Goldman Sachs & Stifel, B. Riley Securities, Craig-Hallum, DA Davidson $45.99 4.5M Shares DGII X DGII Digi International Secondary Managers: Piper Sandler $23.46 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial FVRR X FVRR Fiverr Secondary Managers: JPMorgan, Goldman Sachs, Morgan Stanley $279.44 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial DX X DX Dynex Capital Spot Secondary Managers: JPMorgan & JMP Securities $18.35-18.55 3.5M Shares RADA X RADA Rada Electronic Spot Secondary Managers: Jefferies, Baird & Canaccord, AGPR $11.50-11.75 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	NRIX X NRIX Nurix Therapeutics Secondary Managers: JPMorgan, Piper Sandler & Stifel, RBC Capital, Needham $35.91 4M Shares
Fri	No deals

View All Syndicate Announcements »

Diamondback Energy upgraded to Outperform from Market Perform at BMO Capital

TODAY'S FREE FLY STORIES

Get Full Fly Access